GALDERMA
8.3.2019 15:02:05 CET | Business Wire | Press release
Galderma, Nestlé Skin Health’s medical solutions business, presented the final results from a Phase 2b dose-ranging study of nemolizumab, an investigational therapy in adult patients with moderate-to-severe atopic dermatitis (AD), at the late-breaking session of the 2019 American Academy of Dermatology annual meeting (March 1-5).
Nemolizumab is a first-in-class investigational monoclonal antibody that blocks signaling of IL-31, a cytokine that plays a key role in the pathogenesis of moderate-to-severe AD.
Moderate to severe AD is a serious, chronic form of eczema associated with a high burden of disease linked to itch, sleep deprivation and significant quality of life impairment. This double blind, placebo-controlled, 24 week, dose-ranging Phase 2b study enrolled 226 subjects with moderate-to-severe AD not adequately controlled with topical corticosteroids. All groups received concomitant topical corticotherapy.
This study met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scores from baseline compared with placebo. A 73 percent reduction in mean EASI score was observed at Week 24 with nemolizumab compared with 58 percent for placebo.
Nemolizumab was well-tolerated across all dose levels in this trial. The most common adverse events observed were nasopharyngitis and upper respiratory tract infection. Subjects with pre-existing asthma reported an increase in asthma related events; these events were mostly mild and were reversible under treatment.
Nemolizumab-treated subjects showed statistically significant improvements in key secondary efficacy measures compared with placebo after 16 weeks of treatment:
- 33 percent of nemolizumab-treated subjects achieved clear or almost-clear skin as measured by an investigator’s global assessment (IGA) score of 0 or 1, compared with 12 percent of placebo-treated subjects (p=0.008);
- 49 percent of nemolizumab-treated subjects achieved 75 percent reduction in EASI score compared with 19 percent of placebo-treated subjects (p<0.01); and
- 68 percent of nemolizumab-treated subjects achieved at least 4-point reduction in itch, as measured by the pruritus numerical-rating scale (NRS) score, compared with 21 percent reduction in placebo-treated subjects. (p<0.001).
In addition, nemolizumab was associated with a rapid onset of action on AD symptoms: nemolizumab-treated subjects showed early statistically significant improvements in itching and sleep compared with placebo-treated subjects as measured by pruritus NRS and sleep disturbance NRS.
“We are excited by this Phase 2b late-breaking presentation and to be able to report that nemolizumab met all study endpoints in treatment of moderate to severe atopic dermatitis. These new data have added to growing evidence generated with our partner, Chugai, highlighting the importance of the IL-31 pathway as a key driver in moderate to severe atopic dermatitis,” said Thibaud Portal, Ph. D., Global Vice President of Galderma’s Prescription Business.
“The results of this Phase 2b study showed that nemolizumab significantly improved atopic dermatitis signs and very rapidly improved atopic dermatitis symptoms, including pruritus and sleep disturbance. These findings show why nemolizumab is such a promising new investigational drug and how it could be helpful in treating moderate to severe atopic dermatitis,” said Dr. Jonathan I Silverberg, Principal Investigator of the Phase 2b program, from the Department of Dermatology, North Western University, Chicago, IL, USA.
Galderma is now actively preparing for a worldwide Phase 3 pivotal program which will be implemented by mid-2019.
About the IL-31 Pathway and Atopic Dermatitis
Moderate-to-severe
atopic dermatitis (AD), a serious, chronic form of eczema, is a systemic
inflammatory disease characterized by an allergic response driven by a
subset of immune cells called Type 2 helper T cells, or Th2 cells.
IL-31, a cytokine released by Th2 cells, is involved in AD associated
pruritus by interacting with IL-31 receptor alpha expressed by neuron.
IL-31 is also thought to play a role in AD skin inflammation and AD skin
barrier impairment. Moderate-to-severe forms of AD can be characterized
by pronounced cutaneous dryness, and skin lesions marked by redness,
infiltration/papulation, crusting/oozing, and lichenification, with
periods of lesion exacerbation accompanied by intense itching,
scratching, and skin damage that can lead to secondary infections.
Moderate-to-severe AD can negatively impact patients’ lives and is
associated with a high burden to patients particularly with itching,
sleep deprivation and depression.
About Nemolizumab
Nemolizumab, a first-in-class humanized
monoclonal antibody, is directed against the IL-31R alpha, which blocks
signaling from both IL-31. Nemolizumab, initially developed by Chugai,
was subsequently licensed to Nestlé Skin Health in 2016. Nemolizumab is
an investigational agent under clinical development and its safety and
efficacy have not been fully evaluated by any regulatory authority.
About Galderma
Galderma, Nestlé Skin Health’s medical
solutions business, was created in 1981 and is now present in over 100
countries with an extensive product portfolio to treat a range of
dermatological conditions. The company partners with health care
practitioners around the world to meet the skin health needs of people
throughout their lifetime. Galderma is a leader in research and
development of scientifically-defined and medically-proven solutions for
the skin. For more information, please visit www.galderma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190308005203/en/
Contact:
Media : Sébastien Cros, Head of Corporate Communications info@nestleskinhealth.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Grid Dynamics Earns MACH Alliance's 2026 Agent Ready Award for Production-Scale Agentic AI19.8.2026 22:05:00 CEST | Press release
Key Takeaways: Grid Dynamics is named to MACH Alliance's inaugural 2026 Agent Ready cohort. Grid Dynamics won the award for its agentic AI capabilities and for programs delivered at a global food and beverage company and a global payments company. Grid Dynamics delivered the qualifying work through its Grid Dynamics AI Native (GAIN) platforms and Forward Deployed Engineer delivery model. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, today announced it has earned MACH Alliance's 2026 Agent Ready Award, becoming one of 35 companies named in the program's inaugural cohort. Agent Ready is an advanced certification that builds upon MACH Certification, the MACH Alliance's baseline standard for open, composable, and connected technology. The honor recognizes certified members that have moved agentic AI from pilots and demos into production, at scale, with the guardrails enterprise deployment requires. Every award is in
Xsolla Announces Multi-Year Strategic Partnership With the Good Game Club Podcast to Amplify Positive Stories From the Global Games Industry19.8.2026 18:10:00 CEST | Press release
Collaboration Brings Co-Created Episodes, Live Recordings At gamescom And GDC, And Stories From Studios, With Episodes Recorded Across the Globe Xsolla, a global video game commerce company, today announced a multi-year strategic partnership with Good Game Club, the independent, global podcast dedicated to sharing positive stories from the gaming ecosystem. The partnership builds on a broader effort to support the developers, publishers, and creators shaping the future of the games industry in a positive way by supporting good stories from the human side of video game businesses. The partnership spans the global events calendar, with joint podcast recordings planned each year at gamescom in Cologne and the Game Developers Conference (GDC) in San Francisco. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819127662/en/ Graphic: Xsolla Xsolla and Good Game Club will collaborate on recurring editorial segments and deep-dive ep
KAGA FEI Expands Its Software-Embedded Bluetooth Low Energy Module Lineup with ES4L15MA1 and EC4L15MA119.8.2026 16:00:00 CEST | Press release
KAGA FEI Co., Ltd., a global provider of advanced short-range wireless modules, announced today the development of the ES4L15MA1 and EC4L15MA1 Bluetooth Low Energy modules with embedded software for wireless communication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802953307/en/ ES4L15MA1 (left) and EC4L15MA1 (right) sample modules These products are versions of KAGA FEI’s ES4L15BA1 and EC4L15BA1 wireless modules with embedded software, which use Nordic Semiconductor’s nRF54L15. Because the modules include the functions required for Bluetooth Low Energy communication, device manufacturers can develop products in a shorter period without having to develop wireless communication software from scratch. The modules help reduce software development workloads, shorten product development cycles, and lower development costs for a wide range of IoT devices. The need for wireless connectivity in IoT applications is growing acr
Xsolla Introduces Integrated Backend and Global Payment Solutions for Games, With Founding Partner AccelByte19.8.2026 15:00:00 CEST | Press release
Game Developers Can Now Apply For Early Access To The Integrated Solution Ahead Of Launch Xsolla, a global video game commerce company, today introduced integrated backend solutions for game developers through a founding partnership with AccelByte, a fully managed extensible games backend platform, and opened a closed testing program for a combined solution that pairs AccelByte Gaming Services (AGS) with Xsolla's global payments and monetization tools. Select developers can now apply for early access and help shape the integration ahead of its broader launch. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819624666/en/ Graphic: Xsolla As studios scale live games across PC, mobile, console, and the web, managing player persistence, gaming backend, and global transactions adds cost and slows launches. Through the founding partnership with AccelByte, Xsolla brings AccelByte's backend services together with its own payments a
Corpay Cross-Border Named the Official FX Partner of European T20 Premier League19.8.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with the European T20 Premier League (“ETPL”), a new franchise-based tournament sanctioned by the International Cricket Council, created to establish Europe as a dynamic force in the global T20 landscape. Under the agreement, Corpay becomes EPTL’s exclusive and Official Foreign Exchange (FX) Partner, along with being an Official Partner. As the EPTL’s exclusive foreign exchange partner, Corpay Cross-Border will provide the league with comprehensive FX risk management solutions to help mitigate foreign exchange exposure arising from its day-to-day business activities. Corpay Cross-Border’s award-winning platform will also enable the EPTL to streamline global payments through a single point of access. “Corpay Cross-Border is thrilled to be named the exclu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
